Analyst Price Targets — TERN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 27, 2026 12:56 pm | — | Mizuho Securities | $53.00 | $52.92 | TheFly | Terns Pharmaceuticals downgraded to Neutral from Outperform at Mizuho |
| February 9, 2026 11:50 am | — | Leerink Partners | $58.00 | $37.73 | TheFly | Terns Pharmaceuticals initiated with an Outperform at Leerink |
| December 10, 2025 3:15 pm | Akash Tewari | Jefferies | $70.00 | $44.83 | StreetInsider | Terns Pharmaceuticals (TERN) PT Raised to $70 at Jefferies |
| December 9, 2025 1:08 pm | — | Oppenheimer | $58.00 | $42.22 | TheFly | Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer |
| December 9, 2025 12:46 pm | — | BMO Capital | $54.00 | $40.23 | TheFly | Terns Pharmaceuticals price target raised to $54 from $35 at BMO Capital |
| December 9, 2025 12:36 pm | — | Truist Financial | $56.00 | $40.23 | TheFly | Terns Pharmaceuticals price target raised to $56 from $35 at Truist |
| December 9, 2025 11:23 am | — | Mizuho Securities | $54.00 | $40.23 | TheFly | Terns Pharmaceuticals price target raised to $54 from $33 at Mizuho |
| December 9, 2025 11:12 am | — | H.C. Wainwright | $60.00 | $40.23 | TheFly | Terns Pharmaceuticals price target raised to $60 from $20 at H.C. Wainwright |
| December 9, 2025 10:36 am | Etzer Darout | Barclays | $56.00 | $40.23 | TheFly | Terns Pharmaceuticals price target raised to $56 from $36 at Barclays |
| November 28, 2025 11:33 am | Graig Suvannavejh | Mizuho Securities | $33.00 | $28.75 | StreetInsider | Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN) |
Latest News for TERN
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to…
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
All told, the transaction is valued at around $6.7 billion. If all goes well, it'll close this quarter.
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TERN.
U.S. House Trading
No House trades found for TERN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.